AstraZeneca has said its Covid-19 antibody-drug cocktail cut the risk of contracting symptomatic illness by 83 per cent in a long-term follow-up, Reuters reports.

It said the therapy also cut the risk of symptoms worsening when given within three days of first symptoms.